Myeloproliferative Neoplasms and Cardiovascular Disease: A Review

IF 3.8 2区医学 Q2 ONCOLOGY

Current Treatment Options in Oncology Pub Date : 2024-09-16 DOI:10.1007/s11864-024-01255-8

Orly Leiva, Olivia Liu, Sophia Zhou, Joan How, Michelle Lee, Gabriela Hobbs

{"title":"Myeloproliferative Neoplasms and Cardiovascular Disease: A Review","authors":"Orly Leiva, Olivia Liu, Sophia Zhou, Joan How, Michelle Lee, Gabriela Hobbs","doi":"10.1007/s11864-024-01255-8","DOIUrl":null,"url":null,"abstract":"<p>Myeloproliferative neoplasms (MPN) are a heterogenous group of disorders of clonal hematopoiesis characterized by constitutive activation of the JAK/STAT signaling pathway leading to proliferation of blood cells. Cardiovascular disease (CVD) contributes significantly to the morbidity and mortality of patients with MPN. Particularly well-known CVD complications of MPNs are arterial and venous thrombotic events. However, MPNs are also associated with other forms of CVD including atrial fibrillation, heart failure, and pulmonary hypertension. Recent studies have characterized outcomes of patients with MPN and CVD, including acute myocardial infarction (AMI), heart failure, atrial fibrillation, and pulmonary hypertension. Additionally, optimal cardiovascular disease prevention strategies in patients with MPN are not yet clear. Further investigation is warranted to improve CVD outcomes in patients with MPN. Clinicians should be aware of cardiovascular complications of MPN, including thrombotic as well as non-thrombotic complications (heart failure, arrhythmias, pulmonary hypertension).</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":"204 1","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-024-01255-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Myeloproliferative neoplasms (MPN) are a heterogenous group of disorders of clonal hematopoiesis characterized by constitutive activation of the JAK/STAT signaling pathway leading to proliferation of blood cells. Cardiovascular disease (CVD) contributes significantly to the morbidity and mortality of patients with MPN. Particularly well-known CVD complications of MPNs are arterial and venous thrombotic events. However, MPNs are also associated with other forms of CVD including atrial fibrillation, heart failure, and pulmonary hypertension. Recent studies have characterized outcomes of patients with MPN and CVD, including acute myocardial infarction (AMI), heart failure, atrial fibrillation, and pulmonary hypertension. Additionally, optimal cardiovascular disease prevention strategies in patients with MPN are not yet clear. Further investigation is warranted to improve CVD outcomes in patients with MPN. Clinicians should be aware of cardiovascular complications of MPN, including thrombotic as well as non-thrombotic complications (heart failure, arrhythmias, pulmonary hypertension).

Abstract Image

查看原文本刊更多论文

骨髓增生性肿瘤与心血管疾病：综述

骨髓增殖性肿瘤（MPN）是一组异质性的克隆性造血疾病，其特点是 JAK/STAT 信号通路的构成性激活导致血细胞增殖。心血管疾病（CVD）是导致骨髓增生性疾病患者发病和死亡的重要原因。众所周知，多发性骨髓瘤的心血管疾病并发症主要是动脉和静脉血栓事件。然而，多发性骨髓瘤还与其他形式的心血管疾病有关，包括心房颤动、心力衰竭和肺动脉高压。最近的研究显示了 MPN 和心血管疾病患者的结局，包括急性心肌梗死（AMI）、心力衰竭、心房颤动和肺动脉高压。此外，MPN 患者的最佳心血管疾病预防策略尚不明确。为改善 MPN 患者的心血管疾病预后，有必要开展进一步研究。临床医生应注意 MPN 的心血管并发症，包括血栓和非血栓并发症（心力衰竭、心律失常、肺动脉高压）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Treatment Options in Oncology ONCOLOGY-

CiteScore

7.10

自引率

0.00%

发文量

113

审稿时长

>12 weeks

期刊介绍： This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.